Literature DB >> 31119602

NES1/KLK10 and hNIS gene therapy enhanced iodine-131 internal radiation in PC3 proliferation inhibition.

Jiajia Hu1, Wenbin Shen1, Qian Qu1, Xiaochun Fei2, Ying Miao1, Xinyun Huang1, Jiajun Liu1, Yingli Wu3, Biao Li4.   

Abstract

NES1 gene is thought to be a tumor-suppressor gene. Our previous study found that overexpression of NES1 gene in PC3 cell line could slow down the tumor proliferation rate, associated with a mild decrease in BCL-2 expression. The BCL-2 decrease could increase the sensitivity of radiotherapy to tumors. Thus, we supposed to have an "enhanced firepower" effect by combining overexpressed NES1 gene therapy and 131I radiation therapy uptake by overexpressed hNIS protein. We found a weak endogenous expression of hNIS protein in PC3 cells and demonstrated that the low expression of hNIS protein in PC3 cells might be the reason for the low iodine uptake. By overexpressing hNIS in PC3, the radioactive iodine uptake ability was significantly increased. Results of in vitro and in vivo tumor proliferation experiments and 18F-fluorothymidine (18F-FLT) micro-positron emission tomography/computed tomography (micro-PET/CT) imaging showed that the combined NES1 gene therapy and 131I radiation therapy mediated by overexpressed hNIS protein had the best tumor proliferative inhibition effect. Immunohistochemistry showed an obvious decrease of Ki-67 expression and the lowest BCL-2 expression. These data suggest that via inhibition of BCL-2 expression, overexpressed NES1 might enhance the effect of radiation therapy of 131I uptake in hNIS overexpressed PC3 cells.

Entities:  

Keywords:  androgen-independent prostate cancer; normal epithelial cell-specific 1/kallikrein 10; proliferation; radiation therapy; sodium/iodide symporter

Mesh:

Substances:

Year:  2019        PMID: 31119602     DOI: 10.1007/s11684-018-0643-y

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  26 in total

Review 1.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.

Authors:  Peter E Czabotar; Guillaume Lessene; Andreas Strasser; Jerry M Adams
Journal:  Nat Rev Mol Cell Biol       Date:  2014-01       Impact factor: 94.444

2.  Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression.

Authors:  X L Liu; D E Wazer; K Watanabe; V Band
Journal:  Cancer Res       Date:  1996-07-15       Impact factor: 12.701

3.  Colorectal cancer statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Stacey A Fedewa; Dennis J Ahnen; Reinier G S Meester; Afsaneh Barzi; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-03-01       Impact factor: 508.702

4.  Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts.

Authors:  Rui Chen; Daniel D Sjoberg; Yiran Huang; Liping Xie; Liqun Zhou; Dalin He; Andrew J Vickers; Yinghao Sun
Journal:  J Urol       Date:  2016-09-02       Impact factor: 7.450

5.  Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis.

Authors:  Xufeng Chen; Jeffrey Y C Wong; Patty Wong; Eric H Radany
Journal:  Mol Cancer Res       Date:  2011-02-08       Impact factor: 5.852

6.  Prostate cancer, version 2.2014.

Authors:  James L Mohler; Philip W Kantoff; Andrew J Armstrong; Robert R Bahnson; Michael Cohen; Anthony Victor D'Amico; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric Mark Horwitz; Christopher J Kane; Mark H Kawachi; Michael Kuettel; Timothy M Kuzel; Richard J Lee; Arnold W Malcolm; David Miller; Elizabeth R Plimack; Julio M Pow-Sang; David Raben; Sylvia Richey; Mack Roach; Eric Rohren; Stan Rosenfeld; Edward Schaeffer; Eric J Small; Guru Sonpavde; Sandy Srinivas; Cy Stein; Seth A Strope; Jonathan Tward; Dorothy A Shead; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2014-05       Impact factor: 11.908

7.  The role for NES1 serine protease as a novel tumor suppressor.

Authors:  J Goyal; K M Smith; J M Cowan; D E Wazer; S W Lee; V Band
Journal:  Cancer Res       Date:  1998-11-01       Impact factor: 12.701

Review 8.  Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

Authors:  Ethan Basch; D Andrew Loblaw; Thomas K Oliver; Michael Carducci; Ronald C Chen; James N Frame; Kristina Garrels; Sebastien Hotte; Michael W Kattan; Derek Raghavan; Fred Saad; Mary-Ellen Taplin; Cindy Walker-Dilks; James Williams; Eric Winquist; Charles L Bennett; Ted Wootton; R Bryan Rumble; Stacie B Dusetzina; Katherine S Virgo
Journal:  J Clin Oncol       Date:  2014-09-08       Impact factor: 44.544

9.  Castration-resistant prostate cancer: mechanisms, targets, and treatment.

Authors:  Teresa Maria Santos Amaral; Daniela Macedo; Isabel Fernandes; Luis Costa
Journal:  Prostate Cancer       Date:  2012-03-05

10.  Iodine-131 treatment of thyroid cancer cells leads to suppression of cell proliferation followed by induction of cell apoptosis and cell cycle arrest by regulation of B-cell translocation gene 2-mediated JNK/NF-κB pathways.

Authors:  L M Zhao; A X Pang
Journal:  Braz J Med Biol Res       Date:  2017-01-16       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.